ArticleBMC cancer2025

Phase I study of the safety, tolerability, and potential therapeutic dose of OMT-110 for patients with refractory metastatic Colorectal Cancer.

Youngbae Jeon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.